Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-105,000
Closed -$7.04M 2048
2024
Q3
$7.04M Buy
105,000
+69,500
+196% +$5.71M 0.02% 679
2024
Q2
$4.02M Sell
35,500
-27,100
-43% -$3.43M 0.01% 1006
2024
Q1
$8.68M Sell
62,600
-500
-0.8% -$62.9K 0.02% 570
2023
Q4
$7.83M Sell
63,100
-8,000
-11% -$817K 0.01% 734
2023
Q3
$6.63M Buy
+71,100
New +$8.01M 0.01% 786

Other funds holding DXCM

GTS Securities's DXCM Position: Q2 2026 in Review

GTS Securities sold out of DexCom (DXCM) in Q2 2026, closing a stake of 4,362 shares — an estimated $274K sold.

GTS Securities first reported a position in DXCM in Q2 2023 and held it in 10 quarters. The position peaked at $2.63M in Q3 2024. 974 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • GTS Securities reported no remaining DexCom position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 4,362 DexCom shares in Q2 2026, an estimated $274K.
  • GTS Securities first reported a position in DexCom in Q2 2023 and held it in 10 quarters.
  • GTS Securities's DexCom position peaked at $2.63M in Q3 2024.
  • 974 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.